Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

The company's CEO, Marino Garcia, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. Interested parties can access a live webcast of the presentation through the 'News and Events' section of the Investors page on the Dianthus Therapeutics website.

News Market Reaction

-0.12%

1 alert

-0.12% News Effect

On the day this news was published, DNTH declined 0.12%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at the 43^rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.

A live webcast of the Company’s presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn.

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

When is Dianthus Therapeutics (DNTH) presenting at the 2025 J.P. Morgan Healthcare Conference?

Dianthus Therapeutics is presenting on Wednesday, January 15, 2025, at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.

How can investors watch Dianthus Therapeutics' (DNTH) J.P. Morgan Healthcare Conference presentation?

Investors can watch the live webcast through the 'News and Events' section in the Investors area of the Dianthus Therapeutics website.

What will be discussed at Dianthus Therapeutics' (DNTH) J.P. Morgan Healthcare Conference presentation?

Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview at the conference.

What is Dianthus Therapeutics' (DNTH) main focus in drug development?

Dianthus Therapeutics focuses on developing next-generation antibody complement therapeutics for treating severe autoimmune diseases.